Clin Colon Rectal Surg 2012; 25(01): 046-052
DOI: 10.1055/s-0032-1301759
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Irritable Bowel Syndrome: A Review and Update

Kaitlin Occhipinti
1   Department of Gastroenterology, Ochsner Clinic Foundation, New Orleans, Louisiana.
James W. Smith
1   Department of Gastroenterology, Ochsner Clinic Foundation, New Orleans, Louisiana.
› Author Affiliations
Further Information

Publication History

Publication Date:
23 March 2012 (online)


The understanding of irritable bowel syndrome (IBS) has undergone a rapid evolution with scientific advancement. IBS is a common functional bowel disorder that generates a significant health care burden and is the most commonly diagnosed gastrointestinal condition. There are well-established diagnostic criteria and algorithms for the initial evaluation of patients presenting with the symptoms of IBS. The symptoms can be targeted for therapy with a variety of pharmaceutical and nonpharmaceutical agents. Therapy should be individualized for the patient, and the cornerstone for any effective treatment strategy should be the solid patient–physician relationship.

  • References

  • 1 Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344 (24) 1846-1850
  • 2 Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123 (6) 2108-2131
  • 3 Whitehead WE, Burnett CK, Cook III EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41 (11) 2248-2253
  • 4 Drossman DA, Li Z, Andruzzi E , et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38 (9) 1569-1580
  • 5 Brandt LJ, Bjorkman D, Fennerty MB , et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97 (11, Suppl) S7-S26
  • 6 Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2 (6138) 653-654
  • 7 Drossman DA, Corazziari E, Talley NJ , et al. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2nd ed. McLean, VA: Degnon Associates; 2000
  • 8 Brandt LJ, Chey WD, Foxx-Orenstein AE , et al; American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl 1) S1-S35
  • 9 Sanders DS, Carter MJ, Hurlstone DP , et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001; 358 (9292) 1504-1508
  • 10 Biesiekierski JR, Newnham ED, Irving PM , et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106 (3) 508-514, quiz 515
  • 11 Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122 (2) 107-112
  • 12 Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995; 123 (9) 688-697
  • 13 Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1 (8539) 963-965
  • 14 Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002; 97 (11) 2812-2819
  • 15 Ong DK, Mitchell SB, Barrett JS , et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25 (8) 1366-1373
  • 16 Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133 (2) 136-147
  • 17 Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48 (2) 272-282
  • 18 Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98 (4) 750-758
  • 19 Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3) 355-361
  • 20 Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3 (2) 153-156
  • 21 Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40 (1) 86-95
  • 22 Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112 (5) 1714-1743
  • 23 Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8 (4) 409-416
  • 24 Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58 (3) 367-378
  • 25 Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344 (8914) 39-40
  • 26 Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154
  • 27 Drossman DA, Chey WD, Johanson JF , et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29 (3) 329-341
  • 28 Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40 (4) 819-827
  • 29 Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95 (12) 3503-3506
  • 30 Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98 (2) 412-419
  • 31 Pimentel M, Lembo A, Chey WD , et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364 (1) 22-32
  • 32 Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163 (3) 265-274
  • 33 Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55 (5) 1385-1390
  • 34 Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39 (6) 530-536
  • 35 Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997; 32 (6) 765-768
  • 36 Quigley E, Fried M, Gwee KA , et al. Irritable Bowel Syndrome: A Global Perspective. World Gastroenterology Organisation Global Guideline. Munich, Germany: World Gastroenterology Organisation; 2009
  • 37 Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104 (4) 1033-1049, quiz 1050
  • 38 Gaylord SA, Palsson OS, Garland EL , et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011; 106 (9) 1678-1688
  • 39 Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119 (3) 654-660
  • 40 Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26 (7) 724-735